Press Releases InnoCan Pharma Corporation

Equities

INNO

CA45783P5085

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 03:59:59 2026-02-12 pm EST			5-day change	1st Jan Change
7.620 ^CAD	0.00%		+20.57%	+13.73%

Feb. 09	InnoCan Pharma Says Latest LPT-CBD Trial Involving Dogs Published in Peer-Reviewed Journal	MT
Jan. 27	Innocan Pharma Expects Listing on the NYSE American Stock Exchange with Concurrent Offering	MT

Press Releases

Jan. 27	Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering	AQ
Dec. 10	Innocan Pharma Announces Public Filing of Amended Registration Statement for Proposed U.S. Public Offering	AQ
Nov. 27	Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M	AQ
Nov. 26	InnoCan Pharma : Financial Statements as of September 30, 2025	PU
Nov. 26	InnoCan Pharma : MD&A Report For Nine Months Period Ended September 30, 2025	PU
Nov. 24	Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats	AQ
Nov. 20	Innocan Pharma announces promising results of LPT-CBD administered to Gottingen Minipigs, a well-known drug toxicology model	AQ
25-10-24	Innocan Pharma to Present at the 2025 ThinkEquity Conference	AQ
25-10-15	Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan	AQ
25-09-18	Innocan Pharma Partners With a Sanctuary For Injured Animals to Bring Remedy and Hope with its LPT-CBD injection	AQ
25-09-15	Innocan Pharma's Poster on its Liposomal Synthetic CBD Technology Generates Interest at PAINWeek Conference	AQ
25-09-02	CSE Bulletin: Consolidation - InnoCan Pharma Corporation (INNO)	NE
25-08-29	Innocan Pharma Announces Details of Proposed Share Consolidation	AQ
25-08-28	InnoCan Pharma : MD&A Report For Six Months Period Ended June 30, 2025	PU
25-08-28	InnoCan Pharma : Financial Statements as of June 30, 2025	PU
25-08-27	Innocan Pharma Announces First Half Of 2025 Financial Results	AQ
25-08-22	Innocan's Findings to be Showcased in Scientific Poster Reception at PAINWeek 2025 Conference in Las Vegas, Nevada	AQ
25-07-23	Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering	AQ
25-07-03	Innocan Pharma Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs, providing a good translational model and Provides Corporate Update	AQ
25-06-20	Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference	AQ
25-06-16	Innocan Pharma Highlights Breakthrough Narrative Review On Liposomal Synthetic Cbd For Chronic Pain A Novel Non Opioid Analgesic Approach	AQ
25-06-13	Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach	AQ
25-05-29	InnoCan Pharma : MD&A Report For Three Months Period Ended March 31, 2025	PU
25-05-29	InnoCan Pharma : Financial Statements as of March 31, 2025	PU
25-05-28	Innocan Pharma Announces First Quarter 2025 Financial Results with Continued Strong Revenue Growth and Provides Corporate Update	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases InnoCan Pharma Corporation

Equities

INNO

CA45783P5085

Pharmaceuticals

Press Releases

Filters